Brief: Sorrento Reports FDA Authorization To Proceed With Phase 1 Study Of Intravenous STI-9167
25/04/2022 14:45
April 25 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO ANNOUNCES FDA AUTHORIZATION TO PROCEED WITH PHASE
1
STUDY OF INTRAVENOUS STI-9167 (COVISHIELD), A POTENT
NEUTRALIZATION ANTIBODY AGAINST OMICRON BA.2 AND OTHER
SARS-COV-2 VARIANTS OF CONCERN
Source text for Eikon: ID:nGNX3XFcm7
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20